Page last updated: 2024-10-22

amsacrine and Anticipatory Vomiting

amsacrine has been researched along with Anticipatory Vomiting in 1 studies

Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.

Research Excerpts

ExcerptRelevanceReference
"Twenty-nine patients with acute myeloid leukemia (AML) received a salvage therapy of amsacrine plus IDAC and etoposide, while 22 patients with acute lymphoblastic leukemia (ALL) received amsacrine plus IDAC."2.71Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia. ( Ahn, BM; Baek, JH; Jeon, SB; Kim, DH; Kim, JG; Lee, KB; Moon, JH; Sohn, SK; Sung, WJ, 2005)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sung, WJ1
Kim, DH1
Sohn, SK1
Kim, JG1
Baek, JH1
Jeon, SB1
Moon, JH1
Ahn, BM1
Lee, KB1

Trials

1 trial available for amsacrine and Anticipatory Vomiting

ArticleYear
Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:10

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diar

2005